MOBERG DERMA OBTAINS APPROVAL FOR NOVEL TREATMENT FOR NAIL DISEASES

Moberg Derma AB today announced that CE-mark has been granted for the company’s first approved medical device product, used for the treatment of discolored and damaged nails, for example caused by nail fungus (onycomycosis) or nail psoriasis. The CE mark provides authorization to market and sell the product in the EU/EEA.

“The approval is a result of focused development work during several years and is an important milestone for Moberg Derma. We now look forward to launch the product in close cooperation with our partners in the first markets” says Moberg Derma's President and CEO, Peter Wolpert. About the product and nail fungus (onychomycosis) Moberg’s topical nail product is prescription free and has the potential to become first-line treatment for common nail disorders. Safety and efficacy have been demonstrated in several clinical studies including more than 500 patients. The product has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease and afflicts approximately 10% of the general population. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.

Tags: